Bolt Biotherapeutics, Inc. (BOLT)
6.27
+2.08
(+49.64%)
USD |
NASDAQ |
Oct 23, 16:00
6.78
+0.51
(+8.13%)
Pre-Market: 08:36
Bolt Biotherapeutics Max Drawdown (5Y) : 99.51% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.51% |
| August 31, 2026 | 99.51% |
| July 31, 2026 | 99.51% |
| June 30, 2026 | 99.51% |
| May 31, 2026 | 99.51% |
| April 30, 2026 | 99.51% |
| March 31, 2026 | 99.51% |
| February 28, 2026 | 99.44% |
| January 31, 2026 | 99.44% |
| December 31, 2025 | 99.44% |
| November 30, 2025 | 99.44% |
| October 31, 2025 | 99.40% |
| September 30, 2025 | 99.40% |
| August 31, 2025 | 99.40% |
| July 31, 2025 | 99.31% |
| June 30, 2025 | 99.30% |
| May 31, 2025 | 99.27% |
| April 30, 2025 | 99.22% |
| March 31, 2025 | 99.00% |
| February 28, 2025 | 98.85% |
| January 31, 2025 | 98.77% |
| December 31, 2024 | 98.75% |
| November 30, 2024 | 98.60% |
| October 31, 2024 | 98.54% |
| September 30, 2024 | 98.54% |
| Date | Value |
|---|---|
| August 31, 2024 | 98.30% |
| July 31, 2024 | 98.20% |
| June 30, 2024 | 98.17% |
| May 31, 2024 | 98.10% |
| April 30, 2024 | 97.86% |
| March 31, 2024 | 97.86% |
| February 29, 2024 | 97.86% |
| January 31, 2024 | 97.86% |
| December 31, 2023 | 97.86% |
| November 30, 2023 | 97.86% |
| October 31, 2023 | 97.62% |
| September 30, 2023 | 97.56% |
| August 31, 2023 | 97.25% |
| July 31, 2023 | 96.84% |
| June 30, 2023 | 96.84% |
| May 31, 2023 | 96.84% |
| April 30, 2023 | 96.84% |
| March 31, 2023 | 96.84% |
| February 28, 2023 | 96.84% |
| January 31, 2023 | 96.84% |
| December 31, 2022 | 96.84% |
| November 30, 2022 | 96.79% |
| October 31, 2022 | 96.62% |
| September 30, 2022 | 96.47% |
| August 31, 2022 | 96.47% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
| Sarepta Therapeutics, Inc. | 93.33% |
| Anixa Biosciences, Inc. | 70.17% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -70.93 |
| Beta (5Y) | 1.005 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 54.57% |
| Historical Sharpe Ratio (5Y) | -1.116 |
| Historical Sortino (5Y) | -1.554 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 29.91% |